Your browser doesn't support javascript.
loading
The efficacy and safety of interleukin-1 receptor antagonist in stroke patients: A systematic review.
Kazmi, Sareh; Salehi-Pourmehr, Hanieh; Sadigh-Eteghad, Saeed; Farhoudi, Mehdi.
Afiliación
  • Kazmi S; Department of Neuroscience, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Neurosciences Research Center (NSRC), Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Salehi-Pourmehr H; Research Center for Evidence-Base Medicine, Iranian EBM Centre: A JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Sadigh-Eteghad S; Neurosciences Research Center (NSRC), Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Saeed.sadigetegad@gmail.com.
  • Farhoudi M; Neurosciences Research Center (NSRC), Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Farhoudi_m@yahoo.com.
J Clin Neurosci ; 120: 120-128, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38237490
ABSTRACT
Stroke is the leading cause of disability worldwide, yet there is currently no effective treatment available to mitigate its negative consequences. Pro-inflammatory cytokines, such as interleukin-1 (IL-1), are known to play a crucial role in exacerbating the aftermath of stroke. Thus, it is hypothesized that blocking inflammation and administering anti-inflammatory drugs at an optimal time and dosage may improve the long-term quality of life for stroke patients. This systematic review examines the effectiveness and safety of IL-1 receptor antagonist (IL-1Ra), commercially known as "anakinra," in clinical studies involving the treatment of stroke patients. A comprehensive literature search was conducted until October 2023 to identify relevant studies. The search yielded 1403 articles, out of which 598 were removed due to duplication. After a thorough review of 805 titles and abstracts, 797 articles were further excluded, resulting in 8 studies being included in this systematic review. The findings from all the included studies demonstrate that IL-1Ra is safe for use in acute ischemic and hemorrhagic stroke patients, with no significant adverse events reported. Additionally, biomarkers, clinical assessments, serious adverse events (AEs), and non-serious AEs consistently showed more favorable outcomes in IL-1Ra receiving patients. Stroke elevates the levels of several inflammatory cytokines, however, administration of IL-1RA directly or indirectly modulates these markers and improves some clinical outcomes, suggesting a potential therapeutic benefit of this intervention.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Accidente Cerebrovascular / Proteína Antagonista del Receptor de Interleucina 1 Tipo de estudio: Prognostic_studies / Systematic_reviews Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Clin Neurosci Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Accidente Cerebrovascular / Proteína Antagonista del Receptor de Interleucina 1 Tipo de estudio: Prognostic_studies / Systematic_reviews Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Clin Neurosci Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido